Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC006 and PD-1 Inhibitor in Advanced Solid Tumors
NCT06963814Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC006 in solid tumor (advanced stage) (2 arms). Primary endpoint: Incidence of Dose Limiting Toxicities at 24 months. Started Jul 2025; status: recruiting.
02
Drugs
HC006
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06963814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963814.